In recent weeks, the Hong Kong market has faced challenges amid global economic uncertainties and fluctuating investor sentiment. Despite these headwinds, certain growth companies with high insider ownership have demonstrated resilience, making them compelling considerations for investors. When evaluating stocks in such a volatile environment, companies with strong earnings growth and significant insider ownership often stand out due to their potential for alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
Overview: BYD Company Limited, with a market cap of HK$753.40 billion, operates in the automobiles and batteries sectors across China, Hong Kong, Macau, Taiwan, and internationally.
Operations: BYD's revenue segments include CN￥507.52 billion from Automobiles and Related Products and CN￥154.49 billion from Mobile Handset Components, Assembly Service, and Other Products.
Insider Ownership: 30.1%
Earnings Growth Forecast: 15.2% p.a.
BYD's strong insider ownership aligns with its robust growth trajectory, evidenced by a 36.2% earnings increase last year and a forecasted 15.22% annual growth rate. Recent results show significant production and sales volume increases, with August 2024 figures at 366,973 units produced and 373,083 units sold. The strategic partnership with Uber to deploy electric vehicles globally underscores BYD's expansion efforts, while the Thailand plant inauguration highlights its commitment to scaling operations efficiently.
Overview: Techtronic Industries Company Limited designs, manufactures, and markets power tools, outdoor power equipment, and floorcare and cleaning products globally with a market cap of HK$191.68 billion.
Operations: The company's revenue segments include $13.23 billion from Power Equipment and $965.09 million from Floorcare & Cleaning products.
Insider Ownership: 25.4%
Earnings Growth Forecast: 15.3% p.a.
Techtronic Industries demonstrates strong growth potential with high insider ownership, reflected in its recent earnings report showing a net income of US$550.37 million for H1 2024, up from US$475.78 million last year. The company also announced an interim dividend of HKD 1.08 per share and appointed Steven Philip Richman as Executive Director, highlighting robust leadership continuity. Forecasted revenue and profit growth rates surpass the Hong Kong market averages, indicating sustained expansion prospects.
Overview: Akeso, Inc., a biopharmaceutical company with a market cap of HK$50.22 billion, focuses on the research, development, manufacturing, and commercialization of antibody drugs.
Operations: The company generates CN￥1.87 billion from the research, development, production, and sale of biopharmaceutical products.
Insider Ownership: 20.5%
Earnings Growth Forecast: 54.7% p.a.
Akeso, Inc. exemplifies a growth company with high insider ownership, despite recent financial setbacks. For H1 2024, the company reported revenue of CNY 1.02 billion and a net loss of CNY 238.59 million, contrasting sharply with last year's figures. However, Akeso's innovative bi-specific antibody ivonescimab has received priority review for new indications and demonstrated significant clinical value in Phase III trials. This positions Akeso for potential future growth despite current challenges.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SEHK:1211 SEHK:669 and SEHK:9926.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]